Advertisements



Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

Merck shares surge anew on lung cancer advance, while Bristol-Myers stock plummets

The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement......»»

Category: topSource: marketwatchApr 16th, 2018

"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Wikimedia Commons New cancer treatments that harness the body's immune system are ready to go mainstream.  In data presente.....»»

Category: topSource: businessinsiderApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck"s Keytruda Gets Priority Review in Difficult Lung Cancer

Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decisio.....»»

Category: worldSource: nytJul 3rd, 2018

Merck"s (MRK) Keytruda Gets FDA Approval for Cervical Cancer

Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer. Merck MRK has received FDA’s accelerated approval for label.....»»

Category: smallbizSource: nytJun 13th, 2018

AstraZeneca"s Tagrisso Wins EU Nod for First-Line Lung Cancer

AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) m.....»»

Category: personnelSource: nytJun 11th, 2018

What Is Immunotherapy?: Woman With Terminal Breast Cancer Saved by Pioneering Treatment

Doctors gave Judy Perkins months to live, but researchers were able to save her life by harnessing her immune system to attack her cancer......»»

Category: topSource: newsweekJun 5th, 2018

Merck Steals The Show At ASCO 2018 With Impressive Front-Line Lung Cancer Data

Merck Steals The Show At ASCO 2018 With Impressive Front-Line Lung Cancer Data.....»»

Category: topSource: seekingalphaJun 4th, 2018

Merck"s (MRK) Keytruda Lung Cancer Data in Focus at ASCO

Merck (MRK) presents data from several cancer studies of its .....»»

Category: dealsSource: nytJun 4th, 2018

Study finds rare gain for tough-to-treat pancreatic cancer

Patients with pancreatic cancer that hadn't spread lived substantially longer on .....»»

Category: topSource: foxnewsJun 4th, 2018

Merck"s Keytruda shows promise for melanoma

Merck said long-term data from its cancer drug Keytruda showed promise in treating advanced melanoma patients. Fred Katayama reports......»»

Category: videoSource: reutersJun 4th, 2018

Merck Wins Again - Forbes

ForbesMerck Wins AgainForbesBy Matthew Herper and Ellie Kincaid. Combining Merck's cancer immunotherapy Keytruda with chemotherapy extends the lives of patient.....»»

Category: topSource: googlenewsJun 3rd, 2018

Lung Cancer Drug From Merck Solidifies Lead in Crowded Field - Bloomberg

KDALLung Cancer Drug From Merck Solidifies Lead in Crowded FieldBloombergIn the race to.....»»

Category: topSource: googlenewsJun 3rd, 2018

3 Things In Biotech, May 26: Immunotherapy Strikes Lung Cancer Yet Again

3 Things In Biotech, May 26: Immunotherapy Strikes Lung Cancer Yet Again.....»»

Category: topSource: seekingalphaMay 27th, 2018

AstraZeneca"s drug extending survival rate in lung cancer patients

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Category: topSource: business-standardMay 26th, 2018

Merck Appears Unstoppable In Treating Front-Line Lung Cancer

Merck Appears Unstoppable In Treating Front-Line Lung Cancer.....»»

Category: topSource: seekingalphaMay 24th, 2018

Immunotherapy: Pros and cons of treating cancer

Some oncologists choose not to mention immunotherapy to dying patients, arguing that scientists first must gather rigorous evidence about the benefits and pitfalls.....»»

Category: topSource: business-standardApr 28th, 2018